Related Experiment Video

Updated: Jun 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives

Kiran Lassi1, Nancy A Dawson

  • 1Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA. kiran.lassi@gmail.com

Future Oncology (London, England)
|April 6, 2011
PubMed

Insights

New treatments are urgently needed for metastatic castration-resistant prostate cancer, a common and deadly cancer. This review covers novel therapeutics showing promise for improving outcomes in patients with this advanced disease.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer is a leading cause of cancer incidence and mortality in US men.
  • Treatment options for advanced prostate cancer, particularly after docetaxel chemotherapy failure, remain limited.
  • Metastatic castration-resistant prostate cancer (mCRPC) presents a significant clinical challenge with a poor prognosis.

Purpose of the Study:

  • To review current data on novel therapeutics for mCRPC.
  • To discuss the potential future role of these new treatments in managing prostate cancer.

Main Methods:

  • Literature review of recent clinical data and therapeutic developments.
  • Analysis of novel agents demonstrating efficacy in mCRPC.

Main Results:

  • Several novel therapeutic agents show promising activity in mCRPC.
  • These agents represent a potential advancement in systemic therapy options.

Conclusions:

  • There is an urgent need for new treatment strategies for mCRPC.
  • Novel therapeutics are emerging as important options for patients with advanced prostate cancer.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...